CN1600357A - Effective position of pilose asiabell root, preparation, medication use and preparation method - Google Patents
Effective position of pilose asiabell root, preparation, medication use and preparation method Download PDFInfo
- Publication number
- CN1600357A CN1600357A CN03160026.3A CN03160026A CN1600357A CN 1600357 A CN1600357 A CN 1600357A CN 03160026 A CN03160026 A CN 03160026A CN 1600357 A CN1600357 A CN 1600357A
- Authority
- CN
- China
- Prior art keywords
- radix codonopsis
- preparation
- effective site
- tablet
- chinese medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims description 24
- 229940079593 drug Drugs 0.000 title 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000011347 resin Substances 0.000 claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000007670 refining Methods 0.000 claims abstract description 3
- 241000756943 Codonopsis Species 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 18
- 239000003826 tablet Substances 0.000 claims description 12
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 9
- 238000013268 sustained release Methods 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 239000002775 capsule Substances 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 238000000638 solvent extraction Methods 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 206010003119 arrhythmia Diseases 0.000 claims description 4
- 230000006793 arrhythmia Effects 0.000 claims description 4
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 230000001154 acute effect Effects 0.000 claims description 3
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 241000208671 Campanulaceae Species 0.000 claims description 2
- 206010007556 Cardiac failure acute Diseases 0.000 claims description 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 238000013270 controlled release Methods 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000008298 dragée Substances 0.000 claims description 2
- 239000007888 film coating Substances 0.000 claims description 2
- 238000009501 film coating Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 239000007903 gelatin capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 150000008282 halocarbons Chemical class 0.000 claims description 2
- 230000000302 ischemic effect Effects 0.000 claims description 2
- 239000013563 matrix tablet Substances 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 238000000874 microwave-assisted extraction Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000003204 osmotic effect Effects 0.000 claims description 2
- 238000005325 percolation Methods 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 239000007940 sugar coated tablet Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 239000002904 solvent Substances 0.000 abstract description 3
- 229930193267 codonoside Natural products 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 14
- 210000004351 coronary vessel Anatomy 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 208000031225 myocardial ischemia Diseases 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 241000007126 Codonopsis pilosula Species 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 230000035487 diastolic blood pressure Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 210000003437 trachea Anatomy 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 2
- 229910001626 barium chloride Inorganic materials 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002183 duodenal effect Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 210000003090 iliac artery Anatomy 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- ATADHKWKHYVBTJ-FVGYRXGTSA-N (R)-adrenaline hydrochloride Chemical compound [H+].[Cl-].CNC[C@H](O)C1=CC=C(O)C(O)=C1 ATADHKWKHYVBTJ-FVGYRXGTSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000615546 Codonopsis canescens Species 0.000 description 1
- 241000357628 Codonopsis pilosula subsp. tangshen Species 0.000 description 1
- 241000614992 Codonopsis subglobosa Species 0.000 description 1
- 241001487768 Codonopsis tubulosa Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241001138444 Globularia alypum Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000000274 adsorptive effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000009465 diaoxinxuekang Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
An active component of pilose asiabell root, whose main component is codonoside, is prepared from pilose aisabell root through extracting in water, alcohol, or solvent and refining by macroreticular resin. It can be used to prepare the medicine for preventing and treating cardiovascular and cerebrovascular diseases.
Description
(1) technical field
The present invention relates to a kind of effective site and preparation and preparation method and application of Chinese medicine extraction, be specifically related to Chinese medicine Radix Codonopsis effective site and preparation and the medical usage and the preparation method of a kind of treatment and prevention diseases of cardiovascular and cerebrovascular systems.
(2) background technology
Radix Codonopsis, root for campanulaceae plant Radix Codonopsis (Codonopsis pilosula Nannf.), plain flower Radix Codonopsis (Codonopsispilosula Nannf.var.modesta L.T.Shen), radix codonpsis tangshen (Codonopsis tangshen Oliv.), pipe flower Radix Codonopsis (Codonopsis tubulosa Komar.), globe daisy Radix Codonopsis (Codonopsis subglobosa W.W.Smith), gray wool Radix Codonopsis (Codonopsis canescens Nannf.), sweet in the mouth, property is put down, returning spleen, lung meridian, is Chinese medicine simply.Radix Codonopsis be considered to clinical in representative traditional qi-invigorating herb, Qing Dynasty's " Bencao Congxin ", " book on Chinese herbal medicine justice " are more advocated and are used Radix Codonopsis.And ancient Chinese medicine doctor thinks that the heart is the big masters of the vital organs of the human body, main yang-energy, controlling blood and vessel, and in treatment, QI invigorating belongs to the method for effecting a permanent cure, and by reinforce functional activities of the heart, makes its function of recovering handsome blood operation, reaches the purpose of blood vessels smoothness.We find that in Radix Codonopsis being improved the handicapped systematic study of cardio-cerebrovascular Radix Codonopsis Pilosulae total glucosides pours into anesthetized dog coronary artery ligation myocardial ischemia the anesthetized rat coronary artery ligation again tangible antagonism.Radix Codonopsis Pilosulae total glucosides's energy coronary artery dilator blood vessel, the little blood flow of increase and myocardial nutritional flow amount; Can expand peripheral blood vessel, reduce Peripheral resistance, blood pressure and left ventricular pressure be descended, and can reduce myocardial oxygen consumption, regulate myocardial metabolism; Resist the arrhythmia that multiple factor causes; Improve the activity of lactic acid dehydrogenase and succinate dehydrogenase; Suppress external thrombus and form, reduce packed cell volume, reduce whole blood and plasma viscosity.Animal is acute, the long term toxicity test result shows that toxic and side effects is extremely low.Further, made the composition in the total glycosides clear, and set up the extraction and preparation technique of suitable suitability for industrialized production by chemical constitution study to Radix Codonopsis effective site.
(3) summary of the invention
The object of the present invention is to provide a kind of treatment and the Chinese medicine Radix Codonopsis effective site of prevention diseases of cardiovascular and cerebrovascular systems and the preparation method and the application of preparation thereof.
The Radix Codonopsis effective site of the present invention treatment and prevention diseases of cardiovascular and cerebrovascular systems is to be raw material with the Chinese medicine Radix Codonopsis, by solvent extraction, concentrate, purification is prepared from, total glycosides content is not less than 50% in the products obtained therefrom.Step is as follows: medical material is through after pulverizing, and the pure water mixed solvent of water, methanol, ethanol or arbitrary proportion extracts, and can repeat to extract 1～3 time, remove medicinal residues, normal pressure or concentrating under reduced pressure, concentrated solution obtains Radix Codonopsis effective site with solvent extraction and/or refining with macroporous resin column.
Extracting method can be decoction, backflow, dipping, percolation, microwave extraction or supersound extraction.
Extracting process can be a supercritical CO
2Extraction also can be conventional organic solvent extraction.Organic solvent can be halogenated hydrocarbons, ethyl acetate, methyl acetate or n-butyl alcohol.Reclaim extractant,, obtain Radix Codonopsis effective site 50～100 ℃ of dryings.
Macroporous resin can be various nonpolar, low poles, Semi-polarity, polar homemade or import macroporous adsorbent resin.Macroporous resin column absorption on the concentrated solution, after impurity is removed in washing, reuse alcohol eluting, to the effective ingredient eluting fully till, reclaim eluent, 50～100 ℃ of dryings, obtain Radix Codonopsis effective site.
Chinese medicine Radix Codonopsis effective site adds relevant pharmaceutical aids, can make various peroral dosage forms, comprise capsule, tablet, granule, mixture (oral liquid), syrup, soft extract, drop pill, soft gelatin capsule (soft capsule) agent, pellet, microcapsule, film coating tablet, sugar coated tablet, contain tablet and various slow release formulation, comprise oral sustained release, controlled release forms such as sustained release coating pellet, sustained-release matrix tablet, slow release pulse release tablet, slow release osmotic tablet, sustained release coating tablet, slow releasing capsule.
The medical usage of Radix Codonopsis effective site is to be used for the treatment of and to prevent diseases of cardiovascular and cerebrovascular systems, particularly treats and prevent ischemic cardiovascular, coronary heart disease, angina pectoris, myocardial infarction, arrhythmia and acute and chronic heart failure, cardiac insufficiency.
Advantage of the present invention is: the Radix Codonopsis effective site based on the glucosides constituents that can expect to be used for the treatment of and to prevent the medical usage of cardiovascular and cerebrovascular disease is provided, and has found that it has the effect characteristics of very strong treatment and prevention cardiovascular and cerebrovascular disease.Use extracting method of the present invention, the highly purified Radix Codonopsis effective site (Radix Codonopsis Pilosulae total glucosides's content is more than 50%) of the impurity such as a large amount of monosaccharide, polysaccharide, albumen that can be removed.
(4) description of drawings
Fig. 1 is the process chart of embodiment 1.
Fig. 2 is the process chart of embodiment 2.
Fig. 3 pours into the table that influences of T ripple again to the anesthetized rat coronary artery ligation for Radix Codonopsis effective site.
Fig. 4 is the table that influences of Radix Codonopsis effective site anesthetized dog coronary artery ligation myocardial ischemia ST section.
Fig. 5 is the influence table of Radix Codonopsis effective site to acute myocardial ischemia dog left ventricular function.
Fig. 6 is that Radix Codonopsis effective site is to the hemorheological table that influences of rat blood stasis model.
Fig. 7 brings out the table that influences of rat ventricular to barium chloride for Radix Codonopsis effective site.
Fig. 8 is the process chart of embodiment 8.
Fig. 9 is the process chart of embodiment 9.
(5) specific embodiment
Embodiment 1: the preparation of Radix Codonopsis effective site
Get codonopsis pilosula and be chopped into the 1cm section, 95% alcohol dipping 3 times that adds 10 times of medical material weight, each 48 hours, filter, merge extractive liquid,, 70 ℃ of concentrating under reduced pressure extracting solution are to relative density 1.25～1.30, according to upper prop sample size and wet resin amount (1: 3/W: ratio V), last macroporous adsorptive resins, water is with 2～3ml/cm
28 column volumes of the flow velocity eluting of/min continue with 70% ethanol, 2～3ml/cm
210 column volumes of the flow velocity eluting of/min, 70 ℃ of decompression and solvent recoveries are to cream.Above-mentioned cream in 80 ℃ of reduced vacuum dryings, is promptly got Radix Codonopsis effective site, and yield is no less than 0.5%, (Radix Codonopsis Pilosulae total glucosides's content is more than 50%).Process chart is seen accompanying drawing 1.
Embodiment 2: the preparation of Radix Codonopsis effective site
Get codonopsis pilosula and be chopped into the 1cm section, 95% alcohol dipping 3 times that adds 10 times of medical material weight, each 48 hours, filter, merge extractive liquid,, 70 ℃ of concentrating under reduced pressure extracting solution filter to relative density 1.10～1.15, and filtrate is used the remove impurity of equal-volume petroleum ether extraction, water liquid reuse equal-volume n-butanol extraction, repeat 3 times, merge butanol extraction liquid, 70 ℃ of decompression and solvent recoveries are to cream, with above-mentioned cream in 80 ℃ of reduced vacuum dryings, promptly get Radix Codonopsis effective site, yield is no less than 0.5%, (Radix Codonopsis Pilosulae total glucosides's content is more than 50%).Process chart is seen accompanying drawing 2.
Embodiment 3: Radix Codonopsis effective site is poured into the influence of T ripple again to the anesthetized rat coronary artery ligation
Get 50 of SD rats, 300-350g, ♀ ♂ half and half divides 5 groups at random, the back administration of weighing, the pentobarbital sodium with 0.3% after a hour is anaesthetized 1ml/100g, lies on the back and is fixed on the rat operating-table.Peel off trachea and insert respirator, peel off muscle and expose heart, write down one section electrocardiogram.Ligation rat coronary artery left anterior descending branch, after the record ligation 10,20, behind the 30min electrocardiogram, unclamp ligation rat coronary artery left anterior descending branch and pour into, record is perfusion back 10,20,30min electrocardiogram again, the results are shown in accompanying drawing 3.
Annotate: pour into the back relatively before the normal saline ligation with after the ligation
The Δ ΔP＜0.01; Radix Codonopsis effective site and normal saline are relatively
*P＜0.05,
*P＜0.01
Embodiment 4: Radix Codonopsis effective site is to the influence of anesthetized dog coronary artery ligation myocardial ischemia ST section
Get 20 of dogs, 8-12kg, ♀ ♂ half and half divides 4 groups at random, and 1ml/Kg is anaesthetized with 3% pentobarbital sodium in the back of weighing, and lies on the back and is fixed on the operating-table.Peel off trachea and insert respirator, peel off muscle and expose heart, ligation dog left anterior descending coronary artery writes down one section electrocardiogram.Duodenal administration is after the record administration 30,45,13 the electrocardiogram of 60min.The results are shown in accompanying drawing 4.
Annotate: compare before the administration of Radix Codonopsis effective site with after the administration
ΔP＜0.05,
The Δ ΔP＜0.01; Radix Codonopsis effective site and normal saline are relatively
*P＜0.05,
*P＜0.01
Embodiment 5: Radix Codonopsis effective site is to the influence of acute myocardial ischemia dog left ventricular function
Get 5 of dogs, 8-12kg, 1ml/Kg is anaesthetized with 3% pentobarbital sodium in the back of weighing, and lies on the back and is fixed on the operating-table.Separate femoral vein, insert venous cannulation, slowly import normal saline with microinfusion pump, peel off trachea and insert respirator, separate the left and right sides iliac artery intubate survey left indoor pressure (LVP), left indoor pressure rate of change (dp/dt), the whole last diastolic pressure (LVEDP) in left chamber and iliac artery systolic pressure (SAP), diastolic pressure (DAP) respectively.Dog left side fourth, fifth intercostal is opened breast, 1/3 place ligation on the left anterior descending coronary artery trunk, and 5min measures cardiac output (CO) respectively through duodenal administration after the ligation before and after the ligation.The extremity that needle electrode inserted dog are subcutaneous, and record II lead electrocardiogram is with the thought-read rate.More than the equal synchronous recording of every index on eight road physiology monitors.The results are shown in accompanying drawing 5.
Annotate: compare after the administration of Radix Codonopsis effective site with after the ligation
*P＜0.05,
*P＜0.01.
Embodiment 6: Radix Codonopsis effective site is to the hemorheological influence of rat blood stasis model
Get 60 of SD rats, 260-320g, ♀ ♂ half and half, divide 6 groups at random, normal saline group, model group, Radix Codonopsis effective site low dose, middle dosage, heavy dose, DIAOXINXUE KANG group, administration 7 days removed normal saline group crust injection adrenalin hydrochloride (adr) 0.08ml/100g body weight totally twice down, 4 hours at interval in the 7th day.Between double injection adr, rat put into frozen water 5min in 2 hours, get blood examination inferior morning and survey.
Index: (1) whole blood contrast viscosity; (2) plasma viscosity; (3) packed cell volume
The results are shown in accompanying drawing 6.
Annotate: model group and normal saline are relatively
ΔP＜0.05,
The Δ ΔP＜0.01; Radix Codonopsis effective site and model group are relatively
*P＜0.05
*P＜0.01.
Embodiment 7: Radix Codonopsis effective site is brought out the influence of rat ventricular to barium chloride
Get 20 of rats, ♀ ♂ half and half is divided into 2 groups at random, and administration group gastric infusion Radix Codonopsis effective site with 10% chloral hydrate 300mg/kg intraperitoneal injection of anesthesia, was faced upward the position and is fixed on the Mus platform after 1 hour, traced one section normal II lead electrocardiogram, quiet notes BaCl
2Behind the 4mg/kg, record II lead electrocardiogram changes, and compares two groups of arrhythmia time of occurrences and holds time.The results are shown in accompanying drawing 7.
Annotate: compare with the normal saline group
*P＜0.01.
Embodiment 8: the preparation of Radix Codonopsis effective site capsule
Capsule prescription (every capsules contains):
Radix Codonopsis effective site 100mg
Medical starch 100mg
Micropowder silica gel 50mg
Sodium Hydroxymethyl Stalcs 5mg
Process chart is seen accompanying drawing 8.
Embodiment 9: the preparation of Radix Codonopsis effective site oral liquid
Oral liquid prescription (the 10ml oral liquid contains):
Radix Codonopsis effective site 100mg
Sodium benzoate 25mg
Aspartame 2mg
Process chart is seen accompanying drawing 9.
Claims (8)
1, Chinese medicine Radix Codonopsis effective site and preparation thereof and medical usage and preparation method is characterized in that: the effective site of Radix Codonopsis and preparation thereof, Radix Codonopsis Pilosulae total glucosides's content is more than 50%.
2, the medical usage of Chinese medicine Radix Codonopsis effective site according to claim 1 and preparation thereof is characterized in that: can be as the application of preparation treatment and prevention diseases of cardiovascular and cerebrovascular systems medicine.
3, the medical usage of Chinese medicine Radix Codonopsis effective site according to claim 2 and preparation thereof, it is characterized in that: can be as preparation treatment and prevention ischemic cardiovascular, the application of coronary heart disease, angina pectoris, myocardial infarction, arrhythmia and acute and chronic heart failure, cardiac insufficiency medicine.
4, the preparation method of Chinese medicine Radix Codonopsis effective site according to claim 1, it is characterized in that: the root of getting campanulaceae plant Radix Codonopsis, alcohol, water mixed solvent with arbitrary proportion extract, normal pressure or concentrating under reduced pressure extracting solution, obtain concentrated solution, concentrated solution obtains Radix Codonopsis effective site with solvent extraction and/or refining with macroporous resin column.
5, according to the described method for preparing Chinese medicine Radix Codonopsis effective site of claim 4, it is characterized in that: extracting method can be decoction, backflow, dipping, percolation, microwave extraction or supersound extraction.
6, according to the described method for preparing Chinese medicine Radix Codonopsis effective site of claim 4, it is characterized in that: extracting process can be a supercritical CO
2Extraction also can be conventional organic solvent extraction.
7, according to the method for the described conventional organic solvent extraction of claim 6, it is characterized in that: extractant can be halogenated hydrocarbons, ethyl acetate, methyl acetate or n-butyl alcohol.
8, Chinese medicine Radix Codonopsis effective site according to claim 1 and preparation thereof, it is characterized in that: can make various peroral dosage forms, comprise capsule, tablet, granule, mixture (oral liquid), syrup, soft extract, drop pill, soft gelatin capsule (soft capsule) agent, pellet, microcapsule, film coating tablet, sugar coated tablet, contain tablet and various slow release formulation, comprise oral sustained release, controlled release forms such as sustained release coating pellet, sustained-release matrix tablet, slow release pulse release tablet, slow release osmotic tablet, sustained release coating tablet, slow releasing capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031600263A CN100448457C (en) | 2003-09-23 | 2003-09-23 | Effective position of pilose asiabell root, preparation, medication use and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031600263A CN100448457C (en) | 2003-09-23 | 2003-09-23 | Effective position of pilose asiabell root, preparation, medication use and preparation method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1600357A true CN1600357A (en) | 2005-03-30 |
| CN100448457C CN100448457C (en) | 2009-01-07 |
Family
ID=34660772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031600263A Expired - Fee Related CN100448457C (en) | 2003-09-23 | 2003-09-23 | Effective position of pilose asiabell root, preparation, medication use and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100448457C (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102525950A (en) * | 2012-02-10 | 2012-07-04 | 兰州大学 | Method for preparing pellets of Se-polysaccharides in Codonopsis pilosula |
| CN103040902A (en) * | 2012-12-13 | 2013-04-17 | 大兴安岭林格贝有机食品有限责任公司 | Novel method for purifying wild codonopsis pilosula saponin |
| CN107029005A (en) * | 2016-02-04 | 2017-08-11 | 南京生道源医药科技有限公司 | The preparation method and new application of a kind of Radix Codonopsis extract |
| CN109303785A (en) * | 2018-11-05 | 2019-02-05 | 山东步长制药股份有限公司 | A kind of application of lobetyolin's similar compound in preparation treatment arrhythmia cordis drug |
| CN109315739A (en) * | 2018-11-07 | 2019-02-12 | 中国科学院兰州化学物理研究所 | A kind of fructus lycii Bee Pollen antineoplastic health product and preparation method thereof |
-
2003
- 2003-09-23 CN CNB031600263A patent/CN100448457C/en not_active Expired - Fee Related
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102525950A (en) * | 2012-02-10 | 2012-07-04 | 兰州大学 | Method for preparing pellets of Se-polysaccharides in Codonopsis pilosula |
| CN103040902A (en) * | 2012-12-13 | 2013-04-17 | 大兴安岭林格贝有机食品有限责任公司 | Novel method for purifying wild codonopsis pilosula saponin |
| CN103040902B (en) * | 2012-12-13 | 2016-07-20 | 大兴安岭林格贝寒带生物科技股份有限公司 | A kind of method of the wild Radix Codonopsis saponin of purification |
| CN107029005A (en) * | 2016-02-04 | 2017-08-11 | 南京生道源医药科技有限公司 | The preparation method and new application of a kind of Radix Codonopsis extract |
| CN109303785A (en) * | 2018-11-05 | 2019-02-05 | 山东步长制药股份有限公司 | A kind of application of lobetyolin's similar compound in preparation treatment arrhythmia cordis drug |
| CN109303785B (en) * | 2018-11-05 | 2020-08-14 | 山东步长制药股份有限公司 | Application of lobetyolin analog compound in preparation of medicine for treating arrhythmia |
| CN109315739A (en) * | 2018-11-07 | 2019-02-12 | 中国科学院兰州化学物理研究所 | A kind of fructus lycii Bee Pollen antineoplastic health product and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100448457C (en) | 2009-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100490795C (en) | Red sage root salvianolic acid A injection formulation for treating cardiovascular diseases and preparation process thereof | |
| CN1931236B (en) | Medicine composition of red sage and rhodiola root | |
| CN1462620A (en) | Powder of flenabane and its preparation method as well as application in making drugs | |
| CN101164566B (en) | Peony leaves total glycoside extract, its preparation method and application | |
| CN100448457C (en) | Effective position of pilose asiabell root, preparation, medication use and preparation method | |
| CN101028328A (en) | Production and use for kaki-leaf extract | |
| CN1895307A (en) | Chinese-medicinal extract for treating cardiovascular disease, its preparation and use | |
| CN101099754A (en) | Preparation method and application for pedunculoside II | |
| CN1081922C (en) | Medicinal composition containing ginsenoside Re, preparation and usage thereof | |
| CN100372525C (en) | Frozen dry powder injection of composite salvia miltiorrhiza and its preparation | |
| CN101077363A (en) | Traditional Chinese medicine composition for treating angina pectoris and and preparation method and application thereof | |
| CN100574799C (en) | Radix Ginseng cold limbs injection and preparation method | |
| CN101491563B (en) | Ginseng and pilose antler oral preparation and preparation method thereof | |
| CN100484543C (en) | Medicament composition for treating hepatitis, prepartion method and use | |
| CN1557403A (en) | Medicine for treating angiocardiopathy and cerebrovascular disease and its preparing method | |
| CN101744989B (en) | Method for extracting schisandra chinensis, ginseng and dwarf lilyturf root and preparation thereof | |
| CN108065393A (en) | A kind of food or health food prevented and treat cardiovascular and cerebrovascular disease | |
| CN101745001B (en) | Extraction method of ophiopogon root, ginseng and shiandra and preparation thereof | |
| CN100574754C (en) | A kind of preparation method of total coumarins extract from peucedanum praeruptorm | |
| CN101167784A (en) | Medicinal composition for cardiovascular and cerebrovascular diseases | |
| CN1600755A (en) | General flavones of hawthorn fruit, preparation method and application | |
| CN101745004B (en) | Method for extracting radix ophiopogonis, ginseng and schisandra chinensis as well as preparation thereof | |
| CN1270739C (en) | Freeze drying powder containing red ginseng and accessory piece for injection | |
| CN1915273A (en) | Medicinal composition, preparation method and quality control method | |
| CN1759854A (en) | Chinese materia medica preparation for treating cardiovascular and cerebrovascular diseases, and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Wen Shunfa Document name: Notice of first review |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: YUDAO TECH DEVELEPMENT CO., LTD., NANJING |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110901 Address after: 526020 No. 103, sand street, Zhaoqing, Guangdong Patentee after: ZHAOQING STAR LAKE PHARMACEUTICAL CO.,LTD. Address before: 526020 No. 103, sand street, Zhaoqing, Guangdong Co-patentee before: Nanjing Yudao Technology Development Co.,Ltd. Patentee before: ZHAOQING STAR LAKE PHARMACEUTICAL CO.,LTD. |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090107 Termination date: 20210923 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |